Skip to content
DataLookout
Menu

REDUCyNCT07193420

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Start date changed from estimate of Jun 2026 to Sep 29, 2026
    • Eligibility criteria expanded, about 28 words
    • Primary and study completion pushed from Jun 2030 to Sep 2030
    • Interventions: Cyclophosphamide 35mg/kg/day (Drug), Cyclophosphamide 50mg/kg/day (Drug) to Cyclophosphamide 35mg/kg/day (Drug), Cyclophosphamide 50mg/kg/day (Drug)
    • Secondary endpoints: details revised at 2 of 12 entries
    • Site details revised
  2. Notable Primary and study completion dates: Sep 2029 to Jun 2030
    • Start date: Sep 2025 to Jun 2026
    • Secondary endpoints revised (12)
    • Site contact updated
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

GVHD-free, relapse-free, event-free survival (GREFS)
Timeframe: Day 0 to first occurrence of acute grade III-IV GVHD, severe chronic GVHD, relapse, death, grade 3-4 cardiac event, or grade 3-4 BK virus-associated HC (up to 24 months post-transplant); platelet recovery (>50 × 10^9/L) assessed until Day +60

Secondary (12)

Overall survival (OS)
Quality of life FACT-BMT
Quality of life EQ-5D-5L
Toxicities, infection and hematogical recovery
Cumulative incidence and severity of acute and chronic GVHD assessed according to the 2014 NIH criteria
Show 7 moreShow less
Non-relapse mortality
Cumulative incidence of relapse
Disease-free survival (DFS)
GVHD-free, relapse-free survival (GRFS)
Cost-effectiveness
Cytokine profiles
Gut microbiota

Arms and interventions

Reduced doseExperimental

cyclophosphamide administered at 35mg/kg/day (Adjusted body weight) on days +3 and +4

Standard doseActive comparator

cyclophosphamide administered at 50mg/kg/day (Adjusted Body Weight) on days +3 and +4

Drugs: Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day

Sites

1 site in 1 country

  • Saint Antoine Hospital - Hematology DepartmentParis, France